Table 3. Prognostic Factors of Patients... | American Society of Hematology

Table 3.

Prognostic Factors of Patients With AML for Response to Remission Induction Treatment

	Number of Patients	CR Rate (%)	P Value

WBC
<30	226	58	.019^3-150
30-99	65	57
≥100	27	30
Age
61-69 yrs	194	56	.83^3-150
70-79 yrs	115	56
≤80 yrs	9	44
Performance (WHO)
0	100	66
1	146	54	.008^3-150
2	60	43
3	12	50
AML
De novo	248	56	.96^3-151
Secondary	69	55
Cytogenetics^3-152
NN	87	65	.04^3-151
AN-AA	107	50
Good risk	8	75	.008^3-150
Intermediate risk	63	54
Poor risk	36	36

	Number of Patients	CR Rate (%)	P Value

WBC
<30	226	58	.019^3-150
30-99	65	57
≥100	27	30
Age
61-69 yrs	194	56	.83^3-150
70-79 yrs	115	56
≤80 yrs	9	44
Performance (WHO)
0	100	66
1	146	54	.008^3-150
2	60	43
3	12	50
AML
De novo	248	56	.96^3-151
Secondary	69	55
Cytogenetics^3-152
NN	87	65	.04^3-151
AN-AA	107	50
Good risk	8	75	.008^3-150
Intermediate risk	63	54
Poor risk	36	36

Abbreviations: AML, acute myeloid leukemia; CR, complete remission; WBC, white blood cell count; WHO, World Health Organization; NN, normal; AN, abnormal and normal; AA, abnormal.

F3-150

χ² test for linear trend.

F3-151

χ² test.

F3-152

Cytogenetics was not done or reported or was not successful in 124 patients (CR rate in this group was 54%). Complex chromosome abnormalities were shown in 17 patients of whom 57% attained CR. NN, AA, AN, good risk, intermediate risk, or poor risk categories as defined in Materials and Methods.

View Large

This Feature Is Available To Subscribers Only